Literature DB >> 31837980

Prevalence, diagnosis and outcomes of treatment for primary aldosteronism.

Yuhong Yang1, Martin Reincke1, Tracy Ann Williams2.   

Abstract

Primary aldosteronism (PA) is the most common potentially curable form of hypertension. The overproduction of aldosterone leads to an increased risk of cardiovascular and cerebrovascular events as well as adverse effects to the heart and kidney and psychological disorders. PA is mainly caused by unilateral aldosterone excess due to an aldosterone-producing adenoma or bilateral excess due to bilateral adrenocortical hyperplasia. The diagnostic work-up of PA comprises three steps: screening, confirmatory testing and differentiation of unilateral surgically-correctable forms from medically treated bilateral PA. These specific treatments can mitigate or reverse the increased risks associated with PA. Herein we summarise the prevalence, outcomes and current and future clinical approaches for the diagnosis of primary aldosteronism.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  adrenal venous sampling; aldosterone; aldosterone-producing adenoma; bilateral adrenal hyperplasia; prevalence; renin

Year:  2019        PMID: 31837980     DOI: 10.1016/j.beem.2019.101365

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  12 in total

Review 1.  High Prevalence of Autonomous Aldosterone Production in Hypertension: How to Identify and Treat It.

Authors:  Taweesak Wannachalee; Leedor Lieberman; Adina F Turcu
Journal:  Curr Hypertens Rep       Date:  2022-02-14       Impact factor: 5.369

Review 2.  Primary Aldosteronism: a Continuum from Normotension to Hypertension.

Authors:  Taweesak Wannachalee; Adina F Turcu
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

Review 3.  The Potential Role of Aldosterone-Producing Cell Clusters in Adrenal Disease.

Authors:  Jung Soo Lim; William E Rainey
Journal:  Horm Metab Res       Date:  2020-03-30       Impact factor: 2.936

Review 4.  DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases.

Authors:  Yoshimichi Takeda; Masashi Demura; Takashi Yoneda; Yoshiyu Takeda
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 5.  Functional Characteristic and Significance of Aldosterone-Producing Cell Clusters in Primary Aldosteronism and Age-Related Hypertension.

Authors:  Fatin Athirah Pauzi; Elena Aisha Azizan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-03       Impact factor: 5.555

6.  Outcomes of Adrenalectomy and the Aldosteronoma Resolution Score in the Black and Hispanic Population.

Authors:  Gustavo Romero-Velez; Amanda M Laird; Manuel E Barajas; Mauricio Sierra-Salazar; Miguel F Herrera; Steven K Libutti; Michael K Parides; Xavier Pereira; John C McAuliffe
Journal:  World J Surg       Date:  2021-02-07       Impact factor: 3.352

Review 7.  The Role of Aldosterone in OSA and OSA-Related Hypertension.

Authors:  Yi Wang; Chuan Xiang Li; Ying Ni Lin; Li Yue Zhang; Shi Qi Li; Liu Zhang; Ya Ru Yan; Fang Ying Lu; Ning Li; Qing Yun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

8.  Differences in Glycemic Abnormalities Between Primary Aldosteronism and Essential Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Worapaka Manosroi; Pichitchai Atthakomol; Pittaporn Wattanawitawas; Supawan Buranapin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 6.055

9.  Progress in Primary Aldosteronism 2019: New Players on the Block?

Authors:  Martin Reincke; Felix Beuschlein; Tracy Ann Williams
Journal:  Horm Metab Res       Date:  2020-06-16       Impact factor: 2.936

10.  Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism.

Authors:  Kyoko Teruyama; Mitsuhide Naruse; Mika Tsuiki; Hiroki Kobayashi
Journal:  J Hum Hypertens       Date:  2021-02-09       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.